Introduction

The invention consists of a new fusion peptide structured in order to selectively and efficiently reach the renal district with anti-inflammatory, anti-fibrotic and anti-oxidative effects, independently from glycemic control. The product has been designed for the medical industry, in particular for the treatment of diabetic nephropathy. the number of subjects eligible for treatment extends to 38% of diabetic patients, which in Italy corresponds to about 1,000,000 subjects.

Technical features

The invention consists of a fusion peptide between a derivative of the human protein TIMP3 and a peptide carrier highly selective and efficient for transport to the kidney. This approach allows to restore high TIMP3 activity in the kidney under conditions, such as diabetic nephropathy, in which its reduction is directly related to the disease. The specific delivery may lead to an improvement in the therapeutic index and the pharmacokinetic profile and reduce the systemic adverse effects. In addition, there is currently no specific therapy for diabetic nephropathy, but only  therapies aimed at metabolic and pressure control are considered.

Possible Applications

• Pharmaceutical Industry;
• Health Market.

Advantages

• Increased drug concentration in the kidney;
• Reduction of site effects;
• Reduced invasiveness of the treatment;
• High eligibility and accessibility;
• Significant cost savings.